Navigation Links
IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS
Date:6/12/2009

ients with this chronic condition."

The 103 AS patients from 6 European countries (Belgium, Finland, France, Germany, the Netherlands and the United Kingdom) recruited to the 96-week open-label EASIC (European

Ankylosing Spondylitis Infliximab Cohort) trial had previously participated in the 2-year randomised controlled trial ASSERT (Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy). The EASIC population consisted of 82.5% men and 17.5% women, with a mean age of 43.5 years. There was no major difference between the EASIC and ASSERT study populations in terms of demographics or age.

Between the two trials, patients had a break from their clinical trial-prescribed treatment regime of 1.30.9 years, during which they were treated according to local clinical practice. According to differences in such local standards, one group of patients continued to receive IFX (group 2, n=89, 83 of whom went forward for analysis) and one group did not (group 1, n=14 all analysed). Of the latter, group 1a had relapsed (BASDAI >4 and physician global VAS >4) (n=9) and group 1b were in remission (n=5). Interestingly, all these relapsed patients (group 1a), who had not been treated with IFX during the period between the trials, flared at the time of start of EASIC.

During EASIC, all patients (except for those who had remained in remission) were continuously treated with IFX 5mg/kg (mean dosage) at intervals of 6-8 weeks (at the discretion of the investigator, according to local clinical practice). The patients in group 2 (who had also continuously received IFX between the trials) and completed the trial (n=76) showed significant improvement at week 96 compared to the ASSERT trial baseline data in a number of assessments:

  • BASDAI (Bath AS Disease Activity Index): 6.4 at ASSERT baseline vs 2.5 at week 96 of EASIC (p<0.001)
  • BASFI (Bath AS Functional Index): 5.9 vs 3.1 (p<0.001)
  • BASMI (Bath AS Metrology Index): 4.
    '/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. 30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
3. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
4. Study shows promise for new cancer-stopping therapy
5. MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3&#8482; Healthy Hormones&#8482;
6. Hormone therapy may confer more aggressive properties to prostate tumors
7. Pharmacy Organizations Brief Congress on Medication Therapy Management
8. Vaporized viral vector shows promise in anti-cancer gene therapy
9. Death rates same for diabetes and heart disease patients receiving drug therapy or surgery
10. Cant Sleep? Try Online Therapy
11. Astellas Adds CNS Therapy Area Leader to Global R&D Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Mesa, AZ (PRWEB) , ... August 27, 2015 , ... ... out of more than 2,100 applicants worldwide, selected based on academic rigor, leadership and ... the attainment of a baccalaureate degree. , Sypher will receive a medallion and a ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article ... Association have released new guidelines to educate doctors and patients on the best practices ... particular guidelines came in 2007, so the new version is taking into account nearly ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, at the Adams County ... of the “Music With A Mission” benefit concert. For the past two years, “Music ... the underfunded school districts of Mendon and neighboring town, Quincy, IL. Organized in part ...
(Date:8/27/2015)... ... 2015 , ... StayWell, a leading provider of patient education ... ready and available to all clients. All Krames Patient Education content has been ... targeted and return a more comprehensive data set of content than the ICD-9 ...
(Date:8/27/2015)... ... August 27, 2015 , ... Banc Intranets recently entered into ... will enable both Johnson City, Tenn.-based firms to work synergistically to promote similar products ... product that caters to organizations in the financial, commercial and services sectors. The software, ...
Breaking Medicine News(10 mins):Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4
... international team of pathologists studied an initial 4,000 prostate cancer ... into the natural progression of the disease and how it ... British Journal of Cancer , could be used to develop ... of prostate cancer. Globally, prostate cancer is ...
... people worldwide, researchers say , WEDNESDAY, Sept. 23 (HealthDay ... only one injection produced promising results in animals, U.S. ... to undergo six shots over 28 days -- five ... rabies immunoglobulin. , The new replication-deficient rabies virus vaccine ...
... ... Training from American TeleCare, Inc. to Integrate Telehealth into the Education and Clinical Practice ... ... (ATI), Inc. announced that the Allied Health Department, University of Hawaii-Maui Community College (UH-Maui ...
... BERLIN, Sept. 23 Bayer HealthCare Pharmaceuticals ... today announced the full results from their first collaborative ... Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic ... advanced breast cancer. The data were presented at ...
... ... has been officially recognized by the City of Chicago. In honor of this day, The ... local celebrations. , ... (PRWEB) September 23, 2009 -- Christopher Reeve Day (9/25) has been officially recognized by the ...
... ... MD and Cell Biologist Jose Minguell, PhD,s adult stem cell human clinical ... Stem Cell Summit in Baltimore, MD. All of the trial patients ... diabetic patients reported pain from diabetic neuropathy has ceased. TCA Cellular ...
Cached Medicine News:Health News:Study reveals 2/3 of prostate cancer patients do not need treatment 2Health News:One Shot May Someday Replace Six for Rabies 2Health News:University of Hawaii-Maui Community College Selects American TeleCare for Allied Health Department's Nursing Telehealth Project 2Health News:University of Hawaii-Maui Community College Selects American TeleCare for Allied Health Department's Nursing Telehealth Project 3Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 2Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 3Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 4Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 5Health News:Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study 6Health News:First-Ever Christopher Reeve Day (9/25/09) to be Celebrated with Memorable Chicago Events 2Health News:Louisiana's TCA Cellular Therapy's Findings Reported at World Stem Cell Summit -- Patients' Legs Saved from Amputation Using Adult Stem Cells 2Health News:Louisiana's TCA Cellular Therapy's Findings Reported at World Stem Cell Summit -- Patients' Legs Saved from Amputation Using Adult Stem Cells 3
(Date:8/27/2015)... 27, 2015   NineSigma the leading innovation partner ... in estimated overall revenue growth and anticipates the creation of ... Open Innovation Incentive (OII). In 2013, the ... grant of over $2 million to accelerate adoption of open ... Million and $1 Billion in revenues. To date over 45 ...
(Date:8/27/2015)... 27, 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ... at the Morgan Stanley Global Healthcare Conference on September ... are invited to listen to the live discussion via ... directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded ... after the conclusion of the live event and accessible ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015  Generex Biotechnology ... issuance of a white paper on the status of ... The white paper was presented to the August 19, ... James H. Anderson, Jr. , MD, the Company,s ... online on the Generex website. The white ...
Breaking Medicine Technology:State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... Inc. (Nasdaq: BMRN ) announced today the appointment ... Board of Directors. "We are extremely pleased to ... Directors.  With experience, vision and proven strength in leadership and ... important role in the company," said Pierre Lapalme, Chairman of ...
... NEW YORK and ALLENDALE, N.J., Sept. 23 NeoStem, ... biopharmaceutical company with operations in the U.S. and China ... therapy company that serves the cell therapy industry from ... Jersey and California  today jointly announced the signing of ...
Cached Medicine Technology:BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors 2BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors 3NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 2NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 3NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement 4
... standard in corneal diagnostics. Precise Display ... membrane, stroma, Bowman's membrane and epithelial ... Broad Applications in Surgery and Pathology. ... evaluation, endothelial cell analysis, haze detection, ...
... the appearance of photo-aged skin, removes age ... telangiectasias, and broken capillaries. This innovative new ... treats pigmentary sun damage through a process ... IPL and the Nd:YAG Laser is optimized ...
... fun, affordable lenses available in a ... are available in prescription powers for ... in "Plano" for those who don't. ... Ultrasync technology. Incredibly comfortable, 10 fun, ...
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: